|
1
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bellmunt J, Orsola A, Leow JJ, Wiegel T,
De Santis M and Horwich A; Group EGW; ESMO Guidelines Working
Group: Bladder cancer: ESMO Practice Guidelines for diagnosis,
treatment and follow-up. Ann Oncol. 25(Suppl 3): iii40–iii48. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Riganti C, Gazzano E, Polimeni M, Aldieri
E and Ghigo D: The pentose phosphate pathway: An antioxidant
defense and a crossroad in tumor cell fate. Free Radic Biol Med.
53:421–436. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Tian WN, Braunstein LD, Pang J, Stuhlmeier
KM, Xi QC, Tian X and Stanton RC: Importance of glucose-6-phosphate
dehydrogenase activity for cell growth. J Biol Chem.
273:10609–10617. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hu T, Zhang C, Tang Q, Su Y, Li B, Chen L,
Zhang Z, Cai T and Zhu Y: Variant G6PD levels promote tumor cell
proliferation or apoptosis via the STAT3/5 pathway in the human
melanoma xenograft mouse model. BMC Cancer. 13:2512013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Batetta B, Pulisci D, Bonatesta RR, Sanna
F, Piras S, Mulas MF, Spano O, Putzolu M, Broccia G and Dessì S:
G6PD activity and gene expression in leukemic cells from
G6PD-deficient subjects. Cancer Lett. 140:53–58. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Van Driel BE, Valet GK, Lyon H, Hansen U,
Song JY and Van Noorden CJ: Prognostic estimation of survival of
colorectal cancer patients with the quantitative histochemical
assay of G6PDH activity and the multiparameter classification
program CLASSIF1. Cytometry. 38:176–183. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Polat MF, Taysi S, Gul M, Cikman O, Yilmaz
I, Bakan E and Erdogan F: Oxidant/antioxidant status in blood of
patients with malignant breast tumour and benign breast disease.
Cell Biochem Funct. 20:327–331. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Philipson KA, Elder MG and White JO: The
effects of medroxyprogesterone acetate on enzyme activities in
human endometrial carcinoma. J Steroid Biochem. 23A:1059–1064.
1985. View Article : Google Scholar
|
|
10
|
Zhang C, Zhang Z, Zhu Y and Qin S:
Glucose-6-phosphate dehydrogenase: A biomarker and potential
therapeutic target for cancer. Anticancer Agents Med Chem.
14:280–289. 2014. View Article : Google Scholar
|
|
11
|
Rhodes DR, Yu J, Shanker K, Deshpande N,
Varambally R, Ghosh D, Barrette T, Pandey A and Chinnaiyan AM:
ONCOMINE: A cancer microarray database and integrated data-mining
platform. Neoplasia. 6:1–6. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Dyrskjøt L, Kruhøffer M, Thykjaer T,
Marcussen N, Jensen JL, Møller K and Ørntoft TF: Gene expression in
the urinary bladder: A common carcinoma in situ gene expression
signature exists disregarding histopathological classification.
Cancer Res. 64:4040–4048. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lee JS, Leem SH, Lee SY, Kim SC, Park ES,
Kim SB, Kim SK, Kim YJ, Kim WJ and Chu IS: Expression signature of
E2F1 and its associated genes predict superficial to invasive
progression of bladder tumors. J Clin Oncol. 28:2660–2667. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Fogh J: Cultivation, characterization, and
identification of human tumor cells with emphasis on kidney,
testis, and bladder tumors. Natl Cancer Inst Monogr. 49:5–9.
1978.
|
|
15
|
Bubeník J, Baresová M, Viklický V,
Jakoubková J, Sainerová H and Donner J: Established cell line of
urinary bladder carcinoma (T24) containing tumour-specific antigen.
Int J Cancer. 11:765–773. 1973. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Christian BJ, Loretz LJ, Oberley TD and
Reznikoff CA: Characterization of human uroepithelial cells
immortalized in vitro by simian virus 40. Cancer Res. 47:6066–6073.
1987.PubMed/NCBI
|
|
17
|
Graham FL and van der Eb AJ: A new
technique for the assay of infectivity of human adenovirus 5 DNA.
Virology. 52:456–467. 1973. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)). Method. 25:402–408. 2001. View Article : Google Scholar
|
|
19
|
Loewe S: The problem of synergism and
antagonism of combined drugs. Arzneimittelforschung. 3:285–290.
1953.PubMed/NCBI
|
|
20
|
Tallarida RJ: An overview of drug
combination analysis with isobolograms. J Pharmacol Exp Ther.
319:1–7. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ichijo H, Nishida E, Irie K, ten Dijke P,
Saitoh M, Moriguchi T, Takagi M, Matsumoto K, Miyazono K and Gotoh
Y: Induction of apoptosis by ASK1, a mammalian MAPKKK that
activates SAPK/JNK and p38 signaling pathways. Science. 275:90–94.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Moon DO, Kim MO, Choi YH, Hyun JW, Chang
WY and Kim GY: Butein induces G(2)/M phase arrest and apoptosis in
human hepatoma cancer cells through ROS generation. Cancer Lett.
288:204–213. 2010. View Article : Google Scholar
|
|
23
|
Moloney JN and Cotter TG: ROS signalling
in the biology of cancer. Semin Cell Dev Biol. 80:50–64. 2018.
View Article : Google Scholar
|
|
24
|
Vivanco I and Sawyers CL: The
phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev
Cancer. 2:489–501. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
25
|
Nogueira V, Park Y, Chen CC, Xu PZ, Chen
ML, Tonic I, Unterman T and Hay N: Akt determines replicative
senescence and oxidative or oncogenic premature senescence and
sensitizes cells to oxidative apoptosis. Cancer Cell. 14:458–470.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Calderaro J, Rebouissou S, de Koning L,
Masmoudi A, Hérault A, Dubois T, Maille P, Soyeux P, Sibony M, de
la Taille A, et al: PI3K/AKT pathway activation in bladder
carcinogenesis. Int J Cancer. 134:1776–1784. 2014. View Article : Google Scholar
|
|
27
|
Street JC, Alfieri AA and Koutcher JA:
Quantitation of metabolic and radiobiological effects of
6-aminonicotinamide in RIF-1 tumor cells in vitro. Cancer Res.
57:3956–3962. 1997.PubMed/NCBI
|
|
28
|
Ward PS and Thompson CB: Metabolic
reprogramming: A cancer hallmark even warburg did not anticipate.
Cancer Cell. 21:297–308. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wittig R and Coy JF: The role of glucose
metabolism and glucose-associated signalling in cancer. Perspect
Medicin Chem. 1:64–82. 2008.PubMed/NCBI
|
|
30
|
Giorgio M, Trinei M, Migliaccio E and
Pelicci PG: Hydrogen peroxide: A metabolic by-product or a common
mediator of ageing signals? Nat Rev Mol Cell Biol. 8:722–728. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zorov DB, Juhaszova M and Sollott SJ:
Mitochondrial reactive oxygen species (ROS) and ROS-induced ROS
release. Physiol Rev. 94:909–950. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Vander Heiden MG, Cantley LC and Thompson
CB: Understanding the Warburg effect: The metabolic requirements of
cell proliferation. Science. 324:1029–1033. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kuo W, Lin J and Tang TK: Human
glucose-6-phosphate dehydrogenase (G6PD) gene transforms NIH 3T3
cells and induces tumors in nude mice. Int J Cancer. 85:857–864.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Jiang P, Du W and Yang X: A critical role
of glucose-6-phosphate dehydrogenase in TAp73-mediated cell
proliferation. Cell Cycle. 12:3720–3726. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Rao X, Duan X, Mao W, Li X, Li Z, Li Q,
Zheng Z, Xu H, Chen M, Wang PG, et al: O-GlcNAcylation of G6PD
promotes the pentose phosphate pathway and tumor growth. Nat
Commun. 6:84682015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Song G, Ouyang G and Bao S: The activation
of Akt/PKB signaling pathway and cell survival. J Cell Mol Med.
9:59–71. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Goswami A, Burikhanov R, de Thonel A,
Fujita N, Goswami M, Zhao Y, Eriksson JE, Tsuruo T and Rangnekar
VM: Binding and phosphorylation of par-4 by akt is essential for
cancer cell survival. Mol Cell. 20:33–44. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Sun CH, Chang YH and Pan CC: Activation of
the PI3K/Akt/mTOR pathway correlates with tumour progression and
reduced survival in patients with urothelial carcinoma of the
urinary bladder. Histopathology. 58:1054–1063. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Hothersall JS, Gordge M and Noronha-Dutra
AA: Inhibition of NADPH supply by 6-aminonicotinamide: Effect on
glutathione, nitric oxide and superoxide in J774 cells. FEBS Lett.
434:97–100. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Sharma PK and Varshney R:
2-Deoxy-D-glucose and 6-aminonicotinamide-mediated Nrf2 down
regulation leads to radiosensitization of malignant cells via
abrogation of GSH-mediated defense. Free Radic Res. 46:1446–1457.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Sharma PK, Bhardwaj R, Dwarakanath BS and
Varshney R: Metabolic oxidative stress induced by a combination of
2-DG and 6-AN enhances radiation damage selectively in malignant
cells via non-coordinated expression of antioxidant enzymes. Cancer
Lett. 295:154–166. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Varshney R, Gupta S and Dwarakanath BS:
Radiosensitization of murine Ehrlich ascites tumor by a combination
of 2-deoxy-D-glucose and 6-aminonicotinamide. Technol Cancer Res
Treat. 3:659–663. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Stolfi RL, Colofiore JR, Nord LD, Koutcher
JA and Martin DS: Biochemical modulation of tumor cell energy:
Regression of advanced spontaneous murine breast tumors with a
5-fluoro-uracil-containing drug combination. Cancer Res.
52:4074–4081. 1992.PubMed/NCBI
|
|
44
|
Koutcher JA, Alfieri AA, Stolfi RL, Devitt
ML, Colofiore JR, Nord LD and Martin DS: Potentiation of a three
drug chemotherapy regimen by radiation. Cancer Res. 53:3518–3523.
1993.PubMed/NCBI
|
|
45
|
Poulain L, Sujobert P, Zylbersztejn F,
Barreau S, Stuani L, Lambert M, Palama TL, Chesnais V, Birsen R,
Vergez F, et al: High mTORC1 activity drives glycolysis addiction
and sensitivity to G6PD inhibition in acute myeloid leukemia cells.
Leukemia. 31:2326–2335. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Alfred Witjes J, Lebret T, Compérat EM,
Cowan NC, De Santis M, Bruins HM, Hernández V, Espinós EL, Dunn J,
Rouanne M, et al: Updated 2016 EAU Guidelines on muscle-invasive
and metastatic Bladder Cancer. Eur Urol. 71:462–475. 2017.
View Article : Google Scholar
|
|
47
|
Köberle B, Tomicic MT, Usanova S and Kaina
B: Cisplatin resistance: Preclinical findings and clinical
implications. Biochim Biophys Acta. 1806:172–182. 2010.PubMed/NCBI
|
|
48
|
Liu H, Liu Y and Zhang JT: A new mechanism
of drug resistance in breast cancer cells: Fatty acid synthase
overexpression-mediated palmitate overproduction. Mol Cancer Ther.
7:263–270. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Budihardjo II, Walker DL, Svingen PA,
Buckwalter CA, Desnoyers S, Eckdahl S, Shah GM, Poirier GG, Reid
JM, Ames MM, et al: 6-Aminonicotinamide sensitizes human tumor cell
lines to cisplatin. Clin Cancer Res. 4:117–130. 1998.PubMed/NCBI
|
|
50
|
Catanzaro D, Gaude E, Orso G, Giordano C,
Guzzo G, Rasola A, Ragazzi E, Caparrotta L, Frezza C and Montopoli
M: Inhibition of glucose-6-phosphate dehydrogenase sensitizes
cisplatin-resistant cells to death. Oncotarget. 6:30102–30114.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Zhelev Z, Ivanova D, Bakalova R, Aoki I
and Higashi T: Inhibition of the pentose-phosphate pathway
selectively sensitizes leukemia lymphocytes to chemotherapeutics by
ROS-independent mechanism. Anticancer Res. 36:6011–6020. 2016.
View Article : Google Scholar : PubMed/NCBI
|
